172@29@17@137!~!172@29@0@53!~!|news|business|companies|coronavirus-treatment-sun-pharma-launches-covid-drug-favipiravir-at-rs-35-per-tablet-5644161.html!~!news|moneycontrol|com!~!|controller|infinite_scroll_article.php!~!is_mobile=false
Moneycontrol
Subscribe to PRO at just Rs.33 per month. Use code SUPERPRO
Last Updated : Aug 04, 2020 04:22 PM IST | Source: Moneycontrol.com

Coronavirus treatment | Sun Pharma launches Favipiravir at Rs 35 per tablet

Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate Covid-19 disease, the company said.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Sun Pharma on August 4 said it has launched Favipiravir 200 mg under brand name FluGuard at a price of Rs 35 per tablet, for the treatment of mild to moderate cases of Covid-19 in India.

Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate Covid-19 disease, the company said.

Close

At Rs 35 per tablet, Sun Pharma's Favipiravir version would be the cheapest in the market.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

The DCGI has approved Favipiravir versions of half a dozen companies including Glenmark, Cipla, Hetero, Brinton Pharmaceuticals and Jenburkt, despite clinical trial data from Glenmark not being statistically significant.

Dr Reddy’s had earlier signed with the innovator company Fujifilm to sell the drug.

“With over 50,000 Covid-19 cases being reported daily in India, there is an urgent need to provide more treatment options to healthcare professionals," said Kirti Ganorkar, CEO of India Business of Sun Pharma, said.

"We are launching FluGuard at an economical price to make the drug accessible to more and more patients thereby reducing their financial burden. This is in line with our continuous efforts to support India’s pandemic response," Ganorkar said.

The company said it will work closely with the government and medical community to ensure availability of FluGuard to patients across the country.

The stocks of FluGuard will be available in the market from this week.

First Published on Aug 4, 2020 04:21 pm
Sections